Report overview
The global Omalizumab Monoclonal Antibody Biosimilars market was valued at million in 2024 and is projected to reach US$ million by 2032, at a CAGR of %during the forecast period.
Omalizumab monoclonal antibody biosimilar is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (Fc?RI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
The U.S. market size is estimated at $ million in 2024, while China is to reach $ million.
150 mg/mL segment will reach $ million by 2032, with a % CAGR in next six years.
The global key manufacturers of Omalizumab Monoclonal Antibody Biosimilars include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech, BiosanaPharma, etc. In 2024, the global top five players had a share approximately % in terms of revenue.
We have surveyed the Omalizumab Monoclonal Antibody Biosimilars manufacturers, suppliers, distributors, and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Omalizumab Monoclonal Antibody Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omalizumab Monoclonal Antibody Biosimilars. This report contains market size and forecasts of Omalizumab Monoclonal Antibody Biosimilars in global, including the following market information:
Global Omalizumab Monoclonal Antibody Biosimilars market revenue, 2020-2025, 2026-2032, ($ millions)
Global Omalizumab Monoclonal Antibody Biosimilars market sales, 2020-2025, 2026-2032, (K Units)
Global top five Omalizumab Monoclonal Antibody Biosimilars companies in 2024 (%)
Total Market by Segment:
Global Omalizumab Monoclonal Antibody Biosimilars market, by Type, 2020-2025, 2026-2032 ($ millions) & (K Units)
Global Omalizumab Monoclonal Antibody Biosimilars market segment percentages, by Type, 2024 (%)
150 mg/mL
75 mg/0.5 mL
Global Omalizumab Monoclonal Antibody Biosimilars market, by Application, 2020-2025, 2026-2032 ($ Millions) & (K Units)
Global Omalizumab Monoclonal Antibody Biosimilars market segment percentages, by Application, 2024 (%)
Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria
Global Omalizumab Monoclonal Antibody Biosimilars market, by region and country, 2020-2025, 2026-2032 ($ millions) & (K Units)
Global Omalizumab Monoclonal Antibody Biosimilars market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Omalizumab Monoclonal Antibody Biosimilars revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Omalizumab Monoclonal Antibody Biosimilars revenues share in global market, 2024 (%)
Key companies Omalizumab Monoclonal Antibody Biosimilars sales in global market, 2020-2025 (estimated), (K Units)
Key companies Omalizumab Monoclonal Antibody Biosimilars sales share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Omalizumab Monoclonal Antibody Biosimilars, market overview.
Chapter 2: Global Omalizumab Monoclonal Antibody Biosimilars market size in revenue and volume.
Chapter 3: Detailed analysis of Omalizumab Monoclonal Antibody Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Omalizumab Monoclonal Antibody Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Omalizumab Monoclonal Antibody Biosimilars capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
